FANCM, RAD1, CHEK1 and TP53I3 act as BRCA-like tumor suppressors and are mutated in hereditary ovarian cancer.


Journal

Cancer genetics
ISSN: 2210-7762
Titre abrégé: Cancer Genet
Pays: United States
ID NLM: 101539150

Informations de publication

Date de publication:
06 2019
Historique:
received: 06 02 2019
revised: 27 03 2019
accepted: 18 04 2019
pubmed: 13 5 2019
medline: 7 3 2020
entrez: 13 5 2019
Statut: ppublish

Résumé

Although 25% of ovarian cancer cases are due to inherited factors, most of the genetic risk remains unexplained. We previously identified candidate genes through germline whole exome sequencing of BRCA1/BRCA2 negative ovarian cancer patients with familial risk. Here, we performed functional assessment to determine whether they act as BRCA-like tumor suppressors. Seven candidate risk genes were targeted by siRNA for mRNA depletion followed by functional assays for clonogenic survival, cytotoxicity to DNA damaging agents, and involvement in homologous recombination repair. BRCA1 and BRCA1 were targeted as standards for loss of function outcome. Knockdown of various candidate genes led to tumor suppressor phenotypes also observed in BRCA1/BRCA2 deficient cells. Deficiency of CHEK1, FANCM and TP53I3 led to reduced homologous recombination repair efficiency. Knockdown of RAD1, CHEK1 or FANCM led to a decrease in cellular viability and cells deficient in CHEK1, RAD1 or TP53I3 displayed increased sensitivity to cisplatin. Functional studies of candidate genes identified by whole exome sequencing complements bioinformatics techniques and aid the implication of novel risk loci. The results of this study suggest that genes found mutated in hereditary ovarian cancer, FANCM, RAD1, CHEK1 and TP53I3, act as BRCA-like tumor suppressors.

Identifiants

pubmed: 31078449
pii: S2210-7762(19)30037-7
doi: 10.1016/j.cancergen.2019.04.061
pii:
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
BRCA2 Protein 0
BRCA2 protein, human 0
Intracellular Signaling Peptides and Proteins 0
Proto-Oncogene Proteins 0
RNA, Small Interfering 0
TP53I3 protein, human 0
CHEK1 protein, human EC 2.7.11.1
Checkpoint Kinase 1 EC 2.7.11.1
Exonucleases EC 3.1.-
Rad1 protein, human EC 3.1.11.-
FANCM protein, human EC 3.6.1.-
DNA Helicases EC 3.6.4.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

57-64

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Jaime L Lopes (JL)

Center for Molecular Medicine and Genetics and Department of Oncology, Wayne State University School of Medicine, 421 E. Canfield Street, Suite 3126, Detroit, MI 48201, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Sophia Chaudhry (S)

Center for Molecular Medicine and Genetics and Department of Oncology, Wayne State University School of Medicine, 421 E. Canfield Street, Suite 3126, Detroit, MI 48201, USA.

Guilherme S Lopes (GS)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Nancy K Levin (NK)

Center for Molecular Medicine and Genetics and Department of Oncology, Wayne State University School of Medicine, 421 E. Canfield Street, Suite 3126, Detroit, MI 48201, USA.

Michael A Tainsky (MA)

Center for Molecular Medicine and Genetics and Department of Oncology, Wayne State University School of Medicine, 421 E. Canfield Street, Suite 3126, Detroit, MI 48201, USA. Electronic address: tainskym@karmanos.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH